Global Irritable Bowel Syndrome (IBS) Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI01240901

Publication Date:

January 4, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Irritable Bowel Syndrome (IBS) market size was valued at US$ 4634.2 million in 2023. With growing demand in downstream market, the Irritable Bowel Syndrome (IBS) is forecast to a readjusted size of US$ 12750 million by 2030 with a CAGR of 15.6% during review period.
The research report highlights the growth potential of the global Irritable Bowel Syndrome (IBS) market. Irritable Bowel Syndrome (IBS) are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Irritable Bowel Syndrome (IBS). Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Irritable Bowel Syndrome (IBS) market.
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.
Key Features:
The report on Irritable Bowel Syndrome (IBS) market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Irritable Bowel Syndrome (IBS) market. It may include historical data, market segmentation by Type (e.g., IBS-D Drug, IBS-C Drug), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Irritable Bowel Syndrome (IBS) market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Irritable Bowel Syndrome (IBS) market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Irritable Bowel Syndrome (IBS) industry. This include advancements in Irritable Bowel Syndrome (IBS) technology, Irritable Bowel Syndrome (IBS) new entrants, Irritable Bowel Syndrome (IBS) new investment, and other innovations that are shaping the future of Irritable Bowel Syndrome (IBS).
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Irritable Bowel Syndrome (IBS) market. It includes factors influencing customer ' purchasing decisions, preferences for Irritable Bowel Syndrome (IBS) product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Irritable Bowel Syndrome (IBS) market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Irritable Bowel Syndrome (IBS) market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Irritable Bowel Syndrome (IBS) market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Irritable Bowel Syndrome (IBS) industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Irritable Bowel Syndrome (IBS) market.
Market Segmentation:
Irritable Bowel Syndrome (IBS) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
IBS-D Drug
IBS-C Drug
Others
Segmentation by application
Women
Men
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bausch Health
Allergan
Takeda
Sucampo Pharmaceuticals (Mallinckrodt)
Sebela Pharmaceuticals Inc
Astellas Pharmaceuticals

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Irritable Bowel Syndrome (IBS) Market Size 2019-2030
2.1.2 Irritable Bowel Syndrome (IBS) Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Irritable Bowel Syndrome (IBS) Segment by Type
2.2.1 IBS-D Drug
2.2.2 IBS-C Drug
2.2.3 Others
2.3 Irritable Bowel Syndrome (IBS) Market Size by Type
2.3.1 Irritable Bowel Syndrome (IBS) Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Irritable Bowel Syndrome (IBS) Market Size Market Share by Type (2019-2024)
2.4 Irritable Bowel Syndrome (IBS) Segment by Application
2.4.1 Women
2.4.2 Men
2.5 Irritable Bowel Syndrome (IBS) Market Size by Application
2.5.1 Irritable Bowel Syndrome (IBS) Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Irritable Bowel Syndrome (IBS) Market Size Market Share by Application (2019-2024)
3 Irritable Bowel Syndrome (IBS) Market Size by Player
3.1 Irritable Bowel Syndrome (IBS) Market Size Market Share by Players
3.1.1 Global Irritable Bowel Syndrome (IBS) Revenue by Players (2019-2024)
3.1.2 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Players (2019-2024)
3.2 Global Irritable Bowel Syndrome (IBS) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Irritable Bowel Syndrome (IBS) by Regions
4.1 Irritable Bowel Syndrome (IBS) Market Size by Regions (2019-2024)
4.2 Americas Irritable Bowel Syndrome (IBS) Market Size Growth (2019-2024)
4.3 APAC Irritable Bowel Syndrome (IBS) Market Size Growth (2019-2024)
4.4 Europe Irritable Bowel Syndrome (IBS) Market Size Growth (2019-2024)
4.5 Middle East & Africa Irritable Bowel Syndrome (IBS) Market Size Growth (2019-2024)
5 Americas
5.1 Americas Irritable Bowel Syndrome (IBS) Market Size by Country (2019-2024)
5.2 Americas Irritable Bowel Syndrome (IBS) Market Size by Type (2019-2024)
5.3 Americas Irritable Bowel Syndrome (IBS) Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Irritable Bowel Syndrome (IBS) Market Size by Region (2019-2024)
6.2 APAC Irritable Bowel Syndrome (IBS) Market Size by Type (2019-2024)
6.3 APAC Irritable Bowel Syndrome (IBS) Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Irritable Bowel Syndrome (IBS) by Country (2019-2024)
7.2 Europe Irritable Bowel Syndrome (IBS) Market Size by Type (2019-2024)
7.3 Europe Irritable Bowel Syndrome (IBS) Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Irritable Bowel Syndrome (IBS) by Region (2019-2024)
8.2 Middle East & Africa Irritable Bowel Syndrome (IBS) Market Size by Type (2019-2024)
8.3 Middle East & Africa Irritable Bowel Syndrome (IBS) Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Irritable Bowel Syndrome (IBS) Market Forecast
10.1 Global Irritable Bowel Syndrome (IBS) Forecast by Regions (2025-2030)
10.1.1 Global Irritable Bowel Syndrome (IBS) Forecast by Regions (2025-2030)
10.1.2 Americas Irritable Bowel Syndrome (IBS) Forecast
10.1.3 APAC Irritable Bowel Syndrome (IBS) Forecast
10.1.4 Europe Irritable Bowel Syndrome (IBS) Forecast
10.1.5 Middle East & Africa Irritable Bowel Syndrome (IBS) Forecast
10.2 Americas Irritable Bowel Syndrome (IBS) Forecast by Country (2025-2030)
10.2.1 United States Irritable Bowel Syndrome (IBS) Market Forecast
10.2.2 Canada Irritable Bowel Syndrome (IBS) Market Forecast
10.2.3 Mexico Irritable Bowel Syndrome (IBS) Market Forecast
10.2.4 Brazil Irritable Bowel Syndrome (IBS) Market Forecast
10.3 APAC Irritable Bowel Syndrome (IBS) Forecast by Region (2025-2030)
10.3.1 China Irritable Bowel Syndrome (IBS) Market Forecast
10.3.2 Japan Irritable Bowel Syndrome (IBS) Market Forecast
10.3.3 Korea Irritable Bowel Syndrome (IBS) Market Forecast
10.3.4 Southeast Asia Irritable Bowel Syndrome (IBS) Market Forecast
10.3.5 India Irritable Bowel Syndrome (IBS) Market Forecast
10.3.6 Australia Irritable Bowel Syndrome (IBS) Market Forecast
10.4 Europe Irritable Bowel Syndrome (IBS) Forecast by Country (2025-2030)
10.4.1 Germany Irritable Bowel Syndrome (IBS) Market Forecast
10.4.2 France Irritable Bowel Syndrome (IBS) Market Forecast
10.4.3 UK Irritable Bowel Syndrome (IBS) Market Forecast
10.4.4 Italy Irritable Bowel Syndrome (IBS) Market Forecast
10.4.5 Russia Irritable Bowel Syndrome (IBS) Market Forecast
10.5 Middle East & Africa Irritable Bowel Syndrome (IBS) Forecast by Region (2025-2030)
10.5.1 Egypt Irritable Bowel Syndrome (IBS) Market Forecast
10.5.2 South Africa Irritable Bowel Syndrome (IBS) Market Forecast
10.5.3 Israel Irritable Bowel Syndrome (IBS) Market Forecast
10.5.4 Turkey Irritable Bowel Syndrome (IBS) Market Forecast
10.5.5 GCC Countries Irritable Bowel Syndrome (IBS) Market Forecast
10.6 Global Irritable Bowel Syndrome (IBS) Forecast by Type (2025-2030)
10.7 Global Irritable Bowel Syndrome (IBS) Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Bausch Health
11.1.1 Bausch Health Company Information
11.1.2 Bausch Health Irritable Bowel Syndrome (IBS) Product Offered
11.1.3 Bausch Health Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Bausch Health Main Business Overview
11.1.5 Bausch Health Latest Developments
11.2 Allergan
11.2.1 Allergan Company Information
11.2.2 Allergan Irritable Bowel Syndrome (IBS) Product Offered
11.2.3 Allergan Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Allergan Main Business Overview
11.2.5 Allergan Latest Developments
11.3 Takeda
11.3.1 Takeda Company Information
11.3.2 Takeda Irritable Bowel Syndrome (IBS) Product Offered
11.3.3 Takeda Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Takeda Main Business Overview
11.3.5 Takeda Latest Developments
11.4 Sucampo Pharmaceuticals (Mallinckrodt)
11.4.1 Sucampo Pharmaceuticals (Mallinckrodt) Company Information
11.4.2 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product Offered
11.4.3 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Sucampo Pharmaceuticals (Mallinckrodt) Main Business Overview
11.4.5 Sucampo Pharmaceuticals (Mallinckrodt) Latest Developments
11.5 Sebela Pharmaceuticals Inc
11.5.1 Sebela Pharmaceuticals Inc Company Information
11.5.2 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product Offered
11.5.3 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Sebela Pharmaceuticals Inc Main Business Overview
11.5.5 Sebela Pharmaceuticals Inc Latest Developments
11.6 Astellas Pharmaceuticals
11.6.1 Astellas Pharmaceuticals Company Information
11.6.2 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Offered
11.6.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Astellas Pharmaceuticals Main Business Overview
11.6.5 Astellas Pharmaceuticals Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂